


Impact of real-life use of artificial intelligence as support for human reading in a population-based breast cancer screening program with mammography and tomosynthesis

E Elías-Cabot, S Romero-Martín, JL Raya-Povedano, A.-K. Brehl, M Álvarez-Benito



<u>Study design</u>

Analysis of the performance of double reading screening with mammography and tomosynthesis after implementarion of Transpara as decision support. The study group consisted of a consecutive cohort of 1 year screening between March 2021 and March 2022 where double reading was performed with concurrent Transpara support that automatically detects and highlights lesions suspicious of breast cancer in mammography and tomosynthesis. Screening performance was measured as cancer detection rate (CDR), recall rate (RR), and positive predictive value (PPV) of recalls. Performance in the study group was compared using a McNemar test to a control group that included a screening cohort of the same size, recorded just prior to the implementation of Transpara.



10.0% p < .001 7.5% 5.0% 2.5% 6.1% 5.4% 0.0% With Al No Al

Recall rate

Conclusion

Transpara used as support for human double reading in a real-life breast cancer screening program with DM and DBT increases CDR and PPV of the recalled women.

```
SPM-SMR-001-137 Rev A
```

SCREENPOINT

Medical

© 2023 ScreenPoint Medical BV. Transpara® is a registered trademark of ScreenPoint Medical BV. Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of ScreenPoint Medical. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because ScreenPoint Medical materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products and features are available in a particular country, please contact your local representative or write to info@screenpointmed.com Toernooiveld 300, 6525 EC, Nijmegen, The Netherlands // Tel.: +31 24 202 00 20 // info@screenpointmed.com